Risk/Benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.

Hemoglobin. 2009;33(5):386-97.

Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A.

Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus.

Keywords: oxidative stress, brain, heart, liver, kidneys, classical antioxidants, deferiprone, mobilizing labile iron and copper, free radicals, high therapeutic index, tissue penetration, rapid iron binding, clearance, iron complex, toxicity, cardiomyopathy, thalassemia, diabetic nephropathy, glomerulonephritis, kidney disease, Friedreich's Ataxia, Fanconi Anemia, deferoxamine (DFO), deferasirox (DFRA).